JulieMVoseMDMBA

PubMed

• High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.
  Waseem Lone, Alyssa Bouska, Tyler A Herek, Catalina Amador, Joo Song
  American Journal of Hematology. 2025-01-01
• Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma.
  Limei Poon, Laurence de Leval, Siok Bian Ng, Yuqin Song, Barbara Pro
  Hematological Oncology. 2024-11-01
• 1 citations
  Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms.
  Melissa A Richard, Chengcheng Yan, Yanjun Chen, Christopher J Gibson, Rashi Kalra
  Journal of Clinical Oncology. 2024-11-01

Journal Articles

• Angioimmunoblastic T-cell lymphoma management  
  Mosalpuria K, Bociek RG, Vose JM, Semin Hematol, 1/1/2014
• A multicenter study of primary breast diffuse large B-cell lymphoma in the rituximab era  
  Hosein PJ, Maragulia JC, Salzburg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirahni R, Evens AM, Islam N, Leonard JP, Martin P, Zelenetz Ad, Lossos IS, Br J Haematol, 1/1/2014
• Phase I/II study of Velcade BEAM (V-BEAM) and autologous hematopoietic stem cell transplantation (ASCT) for relapsed indolent non-Hodgkin lymphoma (NHL), transformed o...  
  William BM, Allen MS, Loberiza FR, Bociek RG, Bierman PJ, Armitage JO, Vose JM, Biol Blood Marrow Trans, 1/1/2014
• Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma  
  Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Gujo S, Wilcox RA, The BT, Lim ST, Tna SY, Rimsza LM, Jaffe ES, Campo E, Mar..., Blood, 1/1/2014
• Polo-like Kinase 1: A novel target for the treatment of therapy-resistant mantle cell lymphoma  
  Ahrens, AK, Chaturvedi NK, Shukla A, Nordgren TM, Hegde GV, Vose JM, Joshi SS, Lymphoma, 1/1/2013
• clinicopathologic characteristics of antioimmunoblastic T-cell lymphoma: Analysis of the International Peripheral T-cell Lymphoma Project  
  Massimo F, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage KJ, Weisenburger DD, Armitage JO, Mounier N, Vose JM, J Clinc Oncol, 1/1/2013
• Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: Results from the expanded access program  
  Shaughnessy P, Uberti J, Devise S, Maziarz RT, Vose JM, Micallef I, Jacobsen E, McCarty J, Stiff P, Artiz A, Ball ED, Berryman R, Dugan M, Joyce R, Hsu FJ, Johns D, Mc..., Bone Marrow Transplant, 1/1/2013
•  
  Iqbal J, Weisenburger DD, Chowdhury A, Tsai MY, Srivastava G, Greiner TC, Kucuk C, Deffenbacher K, Vose JM, Smith L, Au Wy, Nakamura S, Seto M, Delabie J, Berger F, Lo..., Leukemia, 1/1/2011
• Non-Hodgkin lymphoma of the prostate  
  Steuter J, Weisenburger DD, Bociek RG, Bierman PJ, Vose JM, Bast M, Loberiza FR, Armitage JO, Am J Hematol, 1/1/2011
• Status of ongoing collaborative efforts  
  Vose JM, Seminars in Hematol, 1/1/2010
• A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B-cell lymphoma: A report from the CIBMTR  
  Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maz..., Biol Blood Marrow Transplant, 1/1/2010
• Time to treatment response in patients with follicular lymphoma treated with Bortezomib is longer compared with other histologic subtypes  
  O’Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Cortelli BM, Blumel S, Evens AM, Zelenetz..., Clin Cancer Res, 1/1/2010
• Understanding evaluation and management of primary cutaneous and systemic ALCL  
  Vose JM, Oncology, 1/1/2010
• NCCN clinical practice guidelines in oncology: Non-Hodgkin's lymphoma  
  Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminsk..., J Natl Compr Canc Netw, 1/1/2010
• Imaging in early stage Hodgkin’s lymphoma  
  Juweid ME, Vose JM, N Engl J Med, 1/1/2010
• Genomic lesions associated with different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21  
  Scandurra M, Mian M, Greiner TC, Rancoita PM, DeCampos CP, Chan WC, Vose JM, Chigrinova E, Inghirami G, Chiappella A, Baldini L, Pnozoni M, Ferreri AJ, Franceschetti S..., Br J Haematol, 1/1/2010
• Late relapse in patients with diffuse large B-cell lymphoma  
  Vose, JM, Weisenburger DD, Loberiza FR, Arevalo A, Bast M, Armitage J, Bierman PJ, Bociek RG, Armitage JO, Br J Haematol, 1/1/2010
• Association of number of follow-up providers with outcomes in survivors of hematologic malignancies  
  Cannon AJ, Darrington DL, McIlvain HE, Bauer LK, Vose, JM, Armitage JO, Lobreiza FR, Leuk & Lymphoma, 1/1/2010
• NCI first international workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the committ...  
  Kroger N, Bacher U, Bader P, Bottcher S, Borowitz MJ, Dreger P, Khouri I, Macapintac H, Olavarria E, Radich J, Stock W, Vose, JM, Weisdorf D, Willasch A, Giralt S, Bis..., Biol Blood Marrow Transplant, 1/1/2010
• The international prognostic index predicts outcome in aggressive adult T-cell leukemia/lymphoma: Analysis of 126 patients from the International Peripheral T-cell Ly...  
  Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Tobinai K, Gascoyne RD, Vose JM, Armitage JO, Weisenburger DD, Ann Oncol, 1/1/2009
• Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-cell Lymphoma Project  
  Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose JM, Armitage JO, Liang R, Blood, 1/1/2009
• Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed...  
  O’Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Cortelli M, Blumel S, Zelenetz AD, Gordon L..., Br J Haematol, 1/1/2009
• The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component  
  Abuzetun JY, Loberiza F, Vose JM, Bierman PJ, Bociek RG, Enke C, Bast M, Weisenburger DD, Armitage JO, Br J Haematol, 1/1/2009
• Tumor-specific recombinant idiotype immunisationi after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma  
  Timmerman JM, Vose JM, Czerwinski DK, Weng W, Ingolia D, Mayo M, Denney DW, Levy R, Leuk and Lymphoma, 1/1/2009
• Does a diffuse growth pattern predict for survival in patients with low-grade follicular lymphoma?  
  Bhagavathi S, Gu K, Loberiza FR, Bast M, Vose JM, Weisenburger DD, Leuk and Lymphoma, 1/1/2009
• Join now to see all

Books/Book Chapters

• Targeted Therapy in Translational Cancer Research 
  Chapter: Lymphoma and targeted therapies 
  Page 169 - 176Smith SM, Vose JMJohn Wiley & Sons, Inc., Hoboken, NJ2016
• Bone Marrow Transplantation 
  Chapter: Hematopoietic stem cell transplantation for non-Hodgkin lymphoma 
  Page 1073 - 1095Bhatt VR, Vose JMElsevier2014
• Neoplastic Diseases of the Blood 
  Chapter: Diagnosis and treatment of non-Hodgkin’s lymphoma of adults 
  Page 1027 - 1047Faber EA, Vose JM, Armitage JO, Bierman PJSpringer Science+Business Media, New York, NYEdition 5th,2013
• Lymphomas 
  Chapter: T-cell Lymphomas 
  Page 211 - 229William BM, Vose JMSpringer Science+Business Media2013
• T-cell Lymphomas 
  Chapter: Epidemiology and prognosis of T-cell lymphoma 
  Page 25 - 39Wang SS, Vose, JMHumana Press, New York, NY2012
• Management of Hematologic Malignancies 
  Chapter: Burkitt lymphoma 
  Page 494 - 502Vose JMEditors: O’Brien, Vose and Kantarjian.Cambridge University Press, New York, NY2011
• Management of Hematologic Malignancies 
  Chapter: Treatment approach to diffuse large B- cell lymphomas 
  Page 286 - 307Smith SM, Vose JMEditors: O’Brien, Vose and Kantarjian.Cambridge University Press, New York, NY2011
• Hodgkin’s Disease 
  Chapter: Other Complications of the Treatment of Hodgkin's Disease 
  Vose JM, Constine LS, Stucliffe SBEditors: Mauch, Armitage, Diehl, Hoppe and Weiss.Lippincott Williams & Wilkins, Philadelphia, PA2006
• Cecil Textbook of Medicine 
  Chapter: Hematopoietic stem cell transplantation. 
  Page 999 - 1003Pavletic SZ and Vose JMEditors: Arend, Armitage, Drazen, Gill, Griggs, Powell, Scheld.Saunders Publishing, Philadelphia, PAEdition 22nd,2004
• Clinical Oncology. 
  Chapter: Bone Marrow Transplantation 
  Page 591 - 601Vose JMEditors: Abeloff, Armitage, Niederhauber, Kastan, McKenna.Elsevier Publishing, Philadelphia, PA2004
• Neoplastic Diseases of the Blood. 
  Chapter: Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. 
  Page 827 - 842Vose JM, Bierman PJ, Armitage JOEditors: Wiernik, Goldman, Dutcher, and Kyle.Cambridge University Press, New York, NY2003
• Monoclonal Antibody Therapy of Hematologic Malignancies 
  Chapter: Strategies for antibody-chemotherapy combinations in non-Hodgkin’s Lymphoma. 
  Page 233 - 242Vose JMEditors: B Cheson.Darwin Scientific Publishing, Oxfordshire, England2001
• Lymphoma 
  Page 76 - 81Vose JMEditors: ED Ball.Churchill Livingstone Inc., New York, NY2000
• Bone Marrow Transplantation 
  Page 482 - 492Vose JM, Kessinger A, Bishop M, Reed EC, Tarantolo S, Bierman P, Armitage JOEditors: M Abeloff, JO Armitage, AS Lichter and JE Niederhuber.W.B. Saunders Co., Philadelphia, PA2000
• Malignant Lymphomas 
  Chapter: High-dose therapy for lymphoma. 
  Page 331 - 350Bierman PJ, Vose JM, Armitage JOEditors: BW Hancock, PJ Selby, K MacLennan, and JO Armitage.Edward Arnold Publishing, London, England2000
• High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells 
  Chapter: Other cytokines (IL-11, thrombopoietin, Flt-3 ligand, and IL-3). 
  Page 467 - 475Vose JMEditors: JO Armitage and KH Antman.Williams and Wilkins, Baltimore, MDEdition 3rd,1999
• Hodgkin’s Disease 
  Chapter: Other complications of the treatment of Hodgkin’s disease. 
  Page 661 - 671Vose JM, Subcliffe S, Constine SEditors: P Mauch, JO Armitage, and R Hoppe.Lippincott-Raven, Philadelphia, PA1999
• Current Therapy in Oncology 
  Editors: JF Foley, JM Vose, and JO Armitage.W.B. Saunders Co., Philadelphia, PA1999
• The Lymphomas 
  Chapter: Bone marrow transplantation for NHL. 
  Page 247 - 260Vose JM, Armitage JOEditors: G Canellos and A Lister.W. B. Saunders Co., Philadelphia, PA1998
• Textbook of Internal Medicine 
  Chapter: Non-Hodgkin’s lymphomas. 
  Page 1395 - 1399Vose JM, Armitage JOEditors: WN Kelley and JH Glick.J. B. Lippincott Publishers, Philadelphia, PAEdition 3rd,1998
• Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies 
  Chapter: The role of autografting in low-grade lymphoma. 
  Page 321 - 328Vose JM, Bierman PJ, Armitage JOEditors: AM Carella.Harwood Academic Publishers1997
• The Non-Hodgkin’s Lymphomas 
  Chapter: Bone marrow transplantation for non-Hodgkin's lymphoma. 
  Page 723 - 737Vose JMEditors: I Magrath.Oxford University Press, New York, NYEdition 2nd,1997
• The Chemotherapy Source Book 
  Chapter: Chemotherapy of non-Hodgkin’s lymphoma. 
  Page 1361 - 1379Armitage JO, Bierman PJ, Vose JMEditors: MC Perry.Williams and Wilkins, Baltimore, MDEdition 2nd,1996
• Proceedings Acute Leukemia V. Experimental Approaches and management of refractory diseases. 
  Chapter: Comparison of front-line chemotherapy for intermediate grade and follicular non-Hodgkin’s lymphoma using the CAP-BOP regimens. 
  Vose JM, Anderson JR, Bierman PJ, Armitage JOEditors: Hiddeman.Springer-Verlag, Berlin Heidelberg1996
• Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases 
  Chapter: Comparison of front-line chemotherapy for intermediate grade and follicular non-Hodgkin’s lymphoma using the CAP-BOP regimens. 
  Page 599 - 603Vose JM, Anderson JR, Bierman PJ, Armitage JOEditors: W Hiddeman, T Bnchne, B Worman, J Ritter, U Creutzig, W Plunkett and M Keating.Springer-Verlag, Berlin, Germany1996
• Join now to see all

Abstracts/Posters

• Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
  Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma
  Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma _ Single Institution Experience
  Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
  Julie M Vose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Interim results from a phase 1-2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
  Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, Lacasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden C, Taft D, Zhang Q, Kato K, Campbell M,..., Hamtol Oncol, 1/1/2017
• Combination of TGR-1202, ublituximab and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma
  Lunning MA, Vose JM, Bierman PJ, Bociek G, Schreeder MT, Siddiqi T, Blumel SM, Cutter K, Pauli EK, Bui D, Sportelli P, Miskin HP, Purdom M, Weiss MS, Fowler NH, Hamtol Oncol, 1/1/2017
• Chemo-free triplet combination of TGR-1202, bulituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL
  Nastoupil L, Lunning, MA, Vose, JM, Schreeder MT, Siddiql T, Flowers CR, Cohen JB Burger JA, Wierda WG, O;’Brien S., Sportelli P, Miskin HP, Purdom MA Weiss MS, Fowler..., Hamtol Oncol, 1/1/2017
• Prognostic factors and impact of etoposide in adults with systemic ALK-positive anaplastic large cell lymphoma: A pooled analysis of six studies
  Siban D, Nguyen, D, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L. Weisenburger D, Nakamura S, Ziepert M, Maurer MJ, Bast M, Armitage JO, Vose JM, Tilly H, Jais..., Hamtol Oncol, 1/1/2017
• Follicular large cleaved cell (centrocytic lymphoma: a distinctive but unrecognized variant of follicular lymphoma
  Weisenburger DD, El Behery R, Laurini JA, Smith LM, Dave BJ, Yuan J, Fu K, Chan WC, Nathwani BN, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Greiner TC, Aoun P, Hamtol Oncol, 1/1/2017
• Comprehensive genomic anlaysis of adult Burkitt lymphoma identifies the B-cell receptor signaling pathway as a potential therapeutic target
  Bouska A, Bi CF, Lone W, Zhang W, Kedwali A, Heavica TB, Lachel CM, Yu J, Fu K, Ferro RA, Eldorghamy N, Greiner TC, Vose JM, Weisenburger DD, Gascoyne RD, Rosenwald A,..., Blood, 1/1/2016
• Gray zone lymphoma (GZL) with reatures intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): Pathologic classification and ...
  Evens AM, Pilichowska M, Pittaluga S, Ferry J, Hemminger J, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Fri..., Blood, 1/1/2016
• CREBBP loss cooperates with BCL2 over-expression to promote lymphoma in mice
  Garcia-Ramirez I, Shrishrimal S, Gonzalez-Herrero I, Martin-Lorenzo A, Rodriguez-Hernandez, Duval R, Moore D, Ruiz-Roca L, Blanco O, Alonso-Lopez D, de Las Rivas J, Kl..., Blood, 1/1/2016
• DNA copy number gains of TCF4 (E2-2) are associated with poor outocome in diffuse large B-cell lymphoma
  Hartert K, Tadros S, Bouska A, Moore D, Pak C, Heavican T, Lui CK. Gentles AJ, Hartmann EM, Kridel R, Ekstrom Smedy K, Juliusson J, Rosenquist R, Gascoyne RD, Rosenwal..., Blood, 1/1/2016
• Molecular subgroups of peripheral T-cell lymphoma evolved by distinct genetic pathways
  Heavican TB, Yu J, Bouska A, Greiner TC, Lachel CM, Wang C, Dave BJ, Amador CC, Fu K, Vose JM, Weisenburger DD, Gascoyne RD, Hartmann S, Pedersen MB, Wilcox R, The BT,..., Blood, 1/1/2016
• Preliminary results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
  Herrera AF, Barlett NL, Ramchandren R, Vose JM, Moskowitz AJ, Feldman TA, LaCasce AS, Anesll SM, Moskowitz CH, Fenton K, Kato K, Fong A, Advani RH, Blood, 1/1/2016
• Combination of ublituximab, TGR-1202 and bendamustine demonstrates significant activity in patients with advanced DLBCL and follicular lymphoma
  Lunning MA, Bierman PJ, Bociek RG, Schreeder MT, Blumel S, Cutter K, Pauli EK, Sportelli P, Miskin HP, Weis MS, Vose JM, Blood, 1/1/2016
• Long term follow up of the P13Ksigma inhibitor TGR-1202 to demonstrate a differentiated safety profile and hight response rates in CLL and NHL: Integrated analysis of...
  Burris, HA,Flinn I, Lunnning MA, Vose JM, Fowler NH, Nastoupil LJ, O’Brien SM, Schreeder MT, Patel MR, Fenske T, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG..., ASCO, 1/1/2016
• Outcomes of patients with diffuse large B-cell lymphoma treated with immunochemotherapy based on cell of origin
  Kallam A, Manikkam Umakanthan J, Lunning MA, Vose JM, Bierman PJ, Fu K, Smith L, Bociek RG, ASCO, 1/1/2016
• Low molecular weiwht heparin (LMWH) use in patients with hematologic malignancyassociated venous thromboembolish (VTE) and sever thrombocytopenia
  Khanal N, Bociek RG, Chen B, Vose JM, Armitage JO, Bierman PJ, Maness LJ, Lunning MA, Gundabolu K, Bhatt VR, ASCO, 1/1/2016
• Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration
  Chea CY, Broeckelmann PJ, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Vose JM, Villa D, Connors JM, Feldman T, Chihara D, Pinnin CC, Milgrom SA, Dabaja BS, Oki Y..., Blood, 1/1/2015
• Tolerability and efficacy of treatmentsin elderly patients with Hodgkin lymphoma: A report from the Nebraska Lymphoma Study Group
  Ferro RA, Bhatt VR, Bast M, Smith L, Bociek RG, Lunning MA, Bierman PJ, Vose JM, Armitage JO, Blood, 1/1/2015
• Overall survival (OS) of acute lymphoblastic leukemia (ALL) is better when initial therapy is administered in academic hospitals (AH) versus non-academic hospitals (NA...
  Ferro RA, Shostrom V, Vose JM, Gundabolu K, Giri S, Islam KM, Maness LJ, Armitage JO, Bhatt VR, Blood, 1/1/2015
• Use of low molecular weight heparin (LMWH) in thrombocytopenic patients with hematologic malignancy-associate venous thromboembolism (VTE)
  Khanal N, Bociek RG, Chen B, Vose JM, Armitage JO, Bierman PJ, Maness LJ, Lunning DO, Gundabolu K, Bhatt VR, Blood, 1/1/2015
• Join now to see all

Lectures

• American Board of Internal Medicine/ASCO Medical Oncology Learning and Assessment: The New... 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
• CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Advances in the Personalized Treatment of Hodgkin and Non-Hodgkin Lymphoma 
  Maui, HI - 1/11/2017
• Advancing women in academic oncology 
  Tampa, FL - 1/3/2017
• Is Hyper-CVAD dead for MCL? What is the best induction and maintenance therapy for MCL 
  Poipu, Kauai, HI - 1/22/2016
• Update on Novel Therapies for Lymphomas 
  Yokohama, Japan - 1/22/2016
• Basket trials: Using genomic methods to direct therapy 
  Poipu, Kauai, HI - 1/21/2016
• ASCO International Department Update 
  Yokohama, Japan - 1/21/2016
• Enhancing value in cancer care 
  Sioux Falls, SD - 1/20/2016
• Hodgkin’s Disease & Non-Hodgkin’s Lymphoma 
  George Washington University Medical Center, Washington, DC - 1/14/2016
• Update on Novel Therapies for Hodgkin and Non-Hodgkin Lymphoma. 
  Wujan, China - 1/14/2016
• Assessing and defining value in cancer care, 
  Maui, HI - 1/12/2016
• Personalizing therapy in lymphomas 
  Maui, HI - 1/10/2016
• Update on peripheral T-cell lymphoma 
  Ohio State University, Columbus, OH - 1/4/2016
• How I treat DLBCL in 2016 
  Dubai - 1/1/2016
• Should we treat DLBCL based on the cell of origin? Yes 
  Dubai - 1/1/2016
• My life and academic career 
  Kyoto, Japan - 1/30/2015
• PTCL: The new single agents – carfilzomib 
  Bologna, Italy - 1/28/2015
• Prognostic models in PTCL 
  Bologna, Italy - 1/27/2015
• New frontiers in imaging: The solution to individualized treatment 
  1/27/2015
• Science-based managementof malignant lymphoma 
  Sapparo, Japan - 1/17/2015
• Join now to see all